North America Biodefense Market Demand, Supply, Growth Factors 2027

The North America biodefense market is anticipated to reach US$ 3,357.83 Mn in 2027 from US$ 1,569.29 Mn in 2019. The market is projected to grow with a CAGR of 10.1% from 2020-2027.

Biodefense Market and Public Health Security

Public Health Security and Market Expansion: The North America biodefense market is witnessing robust growth, driven by the escalating threat posed by infectious diseases. Emerging diseases like SARS, MERS, Ebola, and the ongoing coronavirus pandemic have underscored the critical need for proactive and comprehensive biodefense measures. The public health impact of these outbreaks, with their potential to overwhelm healthcare systems and destabilize economies, is a key driver of market expansion. The sheer scale of these crises necessitates the development of advanced diagnostics, therapeutics, and vaccines, fueling significant investment in the sector. The urgency to protect populations from these threats is paramount.

Get Sample PDF of this Report:

https://www.businessmarketinsights.com/sample/TIPRE00009997

Government Investments and Technological Innovation: Government initiatives, including NIH-supported research, are crucial for driving technological innovation in the North America biodefense market. These investments support the development of cutting-edge diagnostics, novel therapeutics, and advanced vaccines, ensuring rapid and effective responses to biological threats. The agreement between Emergent BioSolutions and Vaxart, focused on an oral coronavirus vaccine candidate, highlights the industry's
commitment to developing innovative solutions. Public-private partnerships are essential for accelerating the pace of innovation and ensuring the timely deployment of countermeasures.

U.S. Market Leadership and National Security: The United States dominates the North America biodefense market, driven by its advanced economy, established biotechnology sector, and substantial government funding. The U.S. military and civilian agencies play a crucial role in ensuring national security by investing in biodefense capabilities. The North America biodefense market is a critical security sector, safeguarding the nation against biological threats. The US invests heavily in the North America biodefense market to maintain its strategic advantage. The North America biodefense market is vital to US stability and resilience in the face of emerging threats.

North America Biodefense Report Scope

Report Attribute        Details

Market size in 2019     US$ 1,569.29 Million

Market Size by 2027    US$ 3,357.83 Million

Global CAGR (2020 - 2027)     10.1%

Historical Data 2017-2018

Forecast period           2020-2027

Segments Covered     By Product

Anthrax

Small pox

Botulism

Radiation/Nuclear

Regions and Countries Covered        

North America

US

Canada

Mexico

Market leaders and key company profiles   

Bavarian Nordic

Alnylam Pharmaceuticals, Inc.

SIGA Technologies

Emergent BioSolutions Inc.

Cleveland Bio Labs

Dynavax Technologies

Elusys Therapeutics, Inc.

Soligenix

Altimmune

Pluristem Therapeutics

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics &

Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, &
Telecommunications